--- title: "Precigen | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 23.25 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286312883.md" datetime: "2026-05-13T20:28:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286312883.md) - [en](https://longbridge.com/en/news/286312883.md) - [zh-HK](https://longbridge.com/zh-HK/news/286312883.md) --- # Precigen | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 23.25 M Revenue: As of FY2026 Q1, the actual value is USD 23.25 M, beating the estimate of USD 20.8 M. EPS: As of FY2026 Q1, the actual value is USD -0.02. EBIT: As of FY2026 Q1, the actual value is USD -3.769 M. ### Revenue - **Total Revenues:** For the three months ended March 31, 2026, total revenues increased to $23,252 thousand, compared to $1,341 thousand for the same period in 2025, marking an increase of $21.9 million. - **Product Revenues, Net:** Product revenues, net, were $21,828 thousand for the three months ended March 31, 2026, a significant increase from $203 thousand in the prior year period. This includes $21.6 million in net product revenue from PAPZIMEOS™. - **Service Revenues:** Service revenues amounted to $1,424 thousand for the three months ended March 31, 2026, up from $1,138 thousand for the same period in 2025. ### Operating Expenses - **Total Operating Expenses:** Total operating expenses were $29,246 thousand for the three months ended March 31, 2026, an increase from $23,937 thousand in the prior year period. - **Cost of Products and Services:** The cost of products and services was $2,559 thousand for the three months ended March 31, 2026, compared to $1,100 thousand in the prior year period. - **Research and Development (R&D):** Research and Development expenses decreased by $4.8 million to $5,638 thousand for the three months ended March 31, 2026, from $10,478 thousand in the prior year period. - **Selling, General, and Administrative (SG&A):** Selling, General, and Administrative expenses increased by $8.7 million to $21,049 thousand for the three months ended March 31, 2026, from $12,359 thousand in the prior year period, primarily due to commercial activities for PAPZIMEOS. ### Operating Loss - The operating loss was -$5,994 thousand for the three months ended March 31, 2026, a reduction from an operating loss of -$22,596 thousand in the prior year period. ### Other Income (Expense), Net - **Total Other Income (Expense), Net:** Total other income (expense), net, was -$1,935 thousand for the three months ended March 31, 2026, significantly improved from -$31,557 thousand in the prior year period. This change reflects the absence of a -$32.5 million charge related to warrant liabilities recorded in the prior year, partially offset by a $2.9 million increase in interest expenses. - **Change in fair value of warrant liabilities:** This was $0 for the three months ended March 31, 2026, compared to -$32,481 thousand in the prior year period. - **Interest expense:** Interest expense was -$2,908 thousand for the three months ended March 31, 2026, compared to -$1 thousand in the prior year period. - **Interest income:** Interest income was $683 thousand for the three months ended March 31, 2026, compared to $918 thousand in the prior year period. - **Other income, net:** Other income, net, was $290 thousand for the three months ended March 31, 2026, compared to $7 thousand in the prior year period. ### Net Loss - The net loss was -$7,929 thousand for the three months ended March 31, 2026, a substantial improvement from a net loss of -$54,153 thousand for the same period in 2025. ### Cash and Investments - Cash, cash equivalents, and investments totaled $56.7 million as of March 31, 2026. - PAPZIMEOS related accounts receivable not yet collected as of March 31, 2026, amounted to approximately $25.7 million. ### Operational Metrics - **PAPZIMEOS Patient Hub Enrollment:** Approximately 400 patients are currently enrolled in the PAPZIMEOS patient hub, with 25% from the community setting. - **PAPZIMEOS Payer Coverage:** Private health plan coverage spans approximately 215 million US lives, and with Medicare and Medicaid, PAPZIMEOS is accessible to an estimated 297 million US lives, or over 90% of insured lives in the US. ### Outlook / Guidance Precigen, Inc. anticipates that its current cash position, combined with expected proceeds from PAPZIMEOS revenue, will fund operations to cash flow break-even by the end of 2026. The company expects continued strength in PAPZIMEOS revenue growth in the second quarter of 2026. Furthermore, Precigen, Inc. plans to provide an AdenoVerse® pipeline update by the end of the year. ### Related Stocks - [PGEN.US](https://longbridge.com/en/quote/PGEN.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)